Among the companies with shares expected to actively trade in
Monday's session are DSW Inc. (DSW), Infinity Pharmaceuticals Inc.
(INFI) and Steel Dynamics Inc. (STLD.
Shoe retailer DSW projected weak fiscal second-quarter earnings,
pointing to more clearance-priced sales as well as costs tied to
its expansion plans. Shares slumped 11% to $52.07 in recent
premarket trading.
Infinity is ending Phase 2 trials of its experimental drug,
saridegib, to treat bone and cartilage cancers, saying results have
been disappointing. Earlier this year, the company discontinued its
Phase 2 studies of saridegib for the treatment of pancreatic
cancer. Shares dropped 18% to $11.40 premarket.
Steel Dynamics forecast second-quarter earnings below analyst
expectations, pointing to a decline in sheet-steel prices. Shares
fell 4.2% to $10.56 premarket.
Women's accessories and apparel retailer Body Central Corp.
(BODY) lowered its already disappointing forecast for the second
quarter, citing soft sales. The company also reduced its full-year
targets as same-store sales in the second quarter are now seen
falling 7% to 9%. Shares slumped 23% to $12.40 in premarket
trade.
Watchlist:
The Food and Drug Administration said its own analysis of
compounded versions of the active ingredient in K-V
Pharmaceuticals's (KVA, KVB) premature-birth prevention Makena drug
did not identify any major safety problems, but reiterated that
approved drugs are generally safer and more effective than
compounded products.
Drug maker Merck & Co. (MRK) said a U.S. district court
ruled against it in a patent-infringement suit involving Apotex
Inc.
PetSmart Inc. (PETM) raised its quarterly dividend 18% and
authorized a new $525 million share buyback, making the retailer
for pet products the latest company to look to boost shareholder
value.
Health-benefits provider WellPoint Inc. (WLP) said it will pay
$90 million to resolve a lawsuit related to its initial public
offering and lowered its full-year earnings projections.
-Write to Mia Lamar at mia.lamar@dowjones.com